OncoMatch/Clinical Trials/NCT07045935

Metabolic Outcomes in Patients With Prolactinomas Under Dopamine Agonist Treatment

Is NCT07045935 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies Cabergoline (Dopamine Agonist) for prolactinoma.

Phase 4RecruitingUniversity Hospital, Basel, SwitzerlandNCT07045935Data as of May 2026

Treatment: Cabergoline (Dopamine Agonist) — This randomized, active-controlled, parallel-arm, single-blind trial is to compare the effects of Dopamine agonists (DA) therapy targeting different established treatment strategies on glucose metabolism assessed by an oral glucose tolerance test.

Check if I qualify

Extracted eligibility criteria

Prior therapy

No prior treatment (treatment-naive required)

Must have received: dopamine agonist (cabergoline)

Patients treated with cabergoline as DA therapy

Lab requirements

Kidney function

Severe renal impairment (eGFR < 30 ml/min)

Liver function

Severe hepatic insufficiency or cholestasis (Child Pugh C or AST/ALT > 3 x ULN or total bilirubin > 2x ULN)

Severe hepatic insufficiency or cholestasis (Child Pugh C or AST/ ALT > 3 x ULN or Cholestasis (total bilirubin > 2x ULN)); Severe renal impairment (eGFR < 30 ml/min)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify